IL-6 receptor antibody

• Catalog Number: orb396139
• Category: Antibodies
• Description: Mouse monoclonal antibody to IL-6 receptor.
• Species/Host: Human
• Clonality: Monoclonal
• Clone Number: rhPM-1 (Tocilizumab)
• Tested applications: ELISA
• Reactivity: Human
• Isotype: IgG1
• Immunogen: The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.
• Concentration: 1 mg/ml
• Purity: Purified
• Conjugation: Unconjugated
• Target: IL-6 receptor
• UniProt ID: P08887
• Storage: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
• Buffer/Preservatives: PBS with 0.02% Proclin 300.
• Alternative names: IL6R; IL-6R; CD126; MRA; atlizumab; TCZ; Interleuk
• Note: For research use only
• Application notes: This antibody is derived from the parental mouse clone PM-1 (PM1). Tocilizumab (TCZ) binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. This antibody is extensively explored for its therapeutic potential in treatment of rheumatoid arthritis (PMID: 25099958; 9836380). Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines. It inhibits sIL-6R and mIL-6R-mediated signaling. A study reported that a combination of tocilizumab and methotrexate (MTX) results in greater inhibition of joint damage and improvement in physical function than does MTX alone (PMID: 21360490). Treatment with tocilizumab results in significant improvement, maintained over time, of polyarticular-course juvenile idiopathic arthritis (pcJIA) signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis (PMID: 24834925).
• Expiration Date: 12 months from date of receipt.

References

Sato, K. et al. Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions Mol Immunol, 31, 371-381 (1994)

PubMed: 8152440